Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Reporting Date: March 2, 2023 (Event Date: February 28, 2023)
Context: The Company entered into an Asset Purchase Agreement with Advanced Facialdontics, LLC ("AFD") to acquire U.S. and international patents, trademarks, product rights, and intellectual property. This acquisition targets the treatment of Temporomandibular Joint Dysfunction (TMD), Bruxism, and Obstructive Sleep Apnea (OSA).
Key Financial Metrics and Transaction Terms
This filing details a strategic acquisition rather than periodic financial performance. No revenue, profit, cash flow, or debt metrics for the Company are provided in this document. The transaction consideration includes:
- Cash Payment: $50,000 upfront.
- Equity Issuance: 250,000 shares of unregistered common stock.
- Warrants: A five-year warrant to purchase up to 400,000 shares at an exercise price of $0.61 per share (subject to vesting milestones).
- Earnouts: Sliding-scale cash payments based on future sales volumes of POD devices and non-POD devices utilizing acquired assets.
- Royalties: Mid-single digit royalty on licensing revenue, with low five-digit quarterly minimums starting in 2024.
- Milestones: Up to $225,000 in aggregate cash payments upon achieving specified FDA authorizations.
- Employment: Hiring of Dr. Scott Simonetti (AFD Founder/CEO) as part-time Senior Director of R&D with an annual salary of $96,000.
Material Changes Versus Prior Period
The filing does not provide comparative financial data or a prior period for analysis. The material change is the expansion of the Company's intellectual property portfolio and product line through the acquisition of AFD's assets, specifically the Preventive Oral Device (POD) and Night Block technologies.
Outlook, Management Commentary, and Risks
Strategic Outlook: Management expects to manufacture acquired products through existing relationships. The acquisition aims to provide complementary treatment options for OSA patients experiencing pain and discomfort, as well as new options for patients with jaw pain and headaches who do not have OSA.
Key Products Acquired:
- POD: FDA 510(k) cleared single-arch device for TMD/Bruxism (estimated 40 million potential patients in U.S./Canada).
- Night Block: FDA 510(k) cleared dual-arch mandibular advancement appliance with unilateral bite block technology.
Risks and Contingencies: Future cash obligations (earnouts, royalties, milestones) are contingent upon sales volumes and the achievement of new FDA authorizations. The warrant shares are subject to vesting based on these same FDA milestones.
Investor Verification Checklist
- Verify the specific sliding-scale percentages for the earnout payments, as the filing only describes them as "low double digits to low single digits."
- Confirm the exact quarterly minimum royalty amounts, described only as "low five-digit."
- Review the specific FDA authorization milestones required to vest the 400,000 warrant shares and trigger the $225,000 in milestone payments.
- Assess the impact of the 250,000 new shares and potential warrant exercise on existing shareholder dilution.
- Monitor the integration of AFD's manufacturing and sales channels with Vivos' existing operations.